14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

14th edition

Format
HYBRID

December 2nd & 3rd, 2025

IN-PERSON | STRASBOURG

December 8th ,2025

ONLINE MEETINGS

Stand G3-F4

2023 Edition

Op2Lysis

Belgium

Op2Lysis is a French-Belgian biotech company developing innovative treatments for patients with cerebrovascular thrombotic diseases, including orphan drug indications. Looking to raise €5M EUR, to complete their €27M EUR Series A round. The proceeds will be to (i) complete a combined Phase 1/2 clinical study of their lead asset O2L-001 in patients with hemorrhagic stroke and (ii) develop pipeline, based on their unique NANOp2Lysis® platform, for other indications including ischemic stroke.

Scroll to Top
  • No products in the cart.